$APYP Update
Press Release | 12/30/2020
APYP quick updates from the CEO.
I expect to have an APYP corporate account with Twitter operational the week of January 4, 2021.
I am working on launching the new APYP website the week of January 11, 2020.
There is no reverse split planned for APYP.
There is no change in the authorized shares of APYP.
APYP has different business focuses based upon prior disclosures, and I plan to address those operations during the CC. I also changed the business description that has been used by the Company below to identify APYP focused industries more easily.
APPYEA Inc is engaged in mobile applications for iOS, Google Play, and Amazon platforms and marketing specific products and services to healthcare providers. The Company operates its titles as well as provides strategic partnerships with promising mobile app developers.
Through its wholly-owned subsidiary, The Diagnostic Centers, Inc., AppYea markets comprehensive diagnostic testing services to physician offices, clinics, hospitals, long term care facilities, healthcare groups, and other healthcare providers.
The Company is also exploring and identifying opportunities to enter the hemp-based Cannabidiol (CBD) industry.
Caution from the CEO:
APYP is an extremely speculative stock. Please be careful when deciding to invest in trading the common shares of APYP on the OTC. There is a possibility you could lose 100% of your investment.
Safe Harbor
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These forward-looking statements are mainly based on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, several of which are beyond management control. Therefore, actual results could differ materially from the forward-looking statements contained in this press release. Additional information respecting the factors that could materially affect the Company and its operations are contained in its annual report on OTC Markets or previously filed on Form 10K and Form 10-Q as filed with the Securities and Exchange Commission. The Company undertakes no obligation to update or revise any forward-looking statement publicly.
Contact information:
Investor Relations
Phone: 800-674-3561 Ext 704 text messaging is available also.
